These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17381411)

  • 1. Biomarkers identified to predict esophageal cancer susceptibility and aspirin found to lower cancer risk.
    Future Oncol; 2007 Apr; 3(2):127. PubMed ID: 17381411
    [No Abstract]   [Full Text] [Related]  

  • 2. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG; Williams L; Guernsey DL
    Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of Barrett's esophagus: can it prevent cancer?
    Sampliner RE
    Surg Oncol Clin N Am; 2009 Jul; 18(3):503-8. PubMed ID: 19500739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NSAIDs, Barrett's oesophagus and adenocarcinoma prevention.
    Vainio H; Morgan G
    Eur J Cancer Prev; 1997 Apr; 6(2):200. PubMed ID: 9237071
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
    Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
    Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [From Barrett esophagus to adenocarcinoma: can the dangers of natural history be overcome?].
    Robaszkiewicz M
    Gastroenterol Clin Biol; 1996; 20(5 Pt 2):B89-97. PubMed ID: 8761127
    [No Abstract]   [Full Text] [Related]  

  • 9. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients.
    Chiang PW; Beer DG; Wei WL; Orringer MB; Kurnit DM
    Clin Cancer Res; 1999 Jun; 5(6):1381-6. PubMed ID: 10389922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and recognition of early esophageal neoplasia.
    Herszényi L; Pregun I; Tulassay Z
    Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort.
    Gatenby PA; Ramus JR; Caygill CP; Winslet MC; Watson A
    Eur J Cancer Prev; 2009 Sep; 18(5):381-4. PubMed ID: 19620873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management strategies for Barrett's esophagus.
    Hillman L
    J Gastroenterol Hepatol; 2007 Jun; 22(6):771-2. PubMed ID: 17565627
    [No Abstract]   [Full Text] [Related]  

  • 14. [Chemoprevention in adenocarcinoma of the esophagus].
    Lanas A; Alcedo González J
    Acta Gastroenterol Latinoam; 2007 Mar; 37(1):37-48. PubMed ID: 17486744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p53, p16 and cyclooxygenase-2 in esophageal cancer with tissue microarray.
    Liu YS; Yu CH; Li L; Zhang BF; Fang J; Zhou Q; Hu Y; Li YM; Jun Gao H
    J Dig Dis; 2007 Aug; 8(3):133-8. PubMed ID: 17650224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias.
    Jankowski J; deCaestecker J; Harrison R; Watson P; Barr H; Attwood S; Moayyedi P
    Lancet Oncol; 2006 Jan; 7(1):7-8; author reply 8-9. PubMed ID: 16389176
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk factors for esophageal cancer development.
    Falk GW
    Surg Oncol Clin N Am; 2009 Jul; 18(3):469-85. PubMed ID: 19500737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
    Bazuro GE; Torino F; Gasparini G; Capurso L
    Minerva Gastroenterol Dietol; 2008 Dec; 54(4):429-44. PubMed ID: 19047983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical evaluation of a panel of tumor cell markers during malignant progression in Barrett esophagus.
    van Dekken H; Hop WC; Tilanus HW; Haringsma J; van der Valk H; Wink JC; Vissers KJ
    Am J Clin Pathol; 2008 Nov; 130(5):745-53. PubMed ID: 18854267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular markers and genetics in cancer development.
    Hormi-Carver K; Souza RF
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.